Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren time-course study in type 2 diabetes with nephropathy
2005-000361-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aliskiren in hypertension (HTN), diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM), sponsored by Novartis. Primary endpoints: Time-course of antiproteinuric effect and Time-course of blood pressure lowering effect. Started Apr 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000361-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000361-19.